Page 6 - Alexey Aleshin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Natera s Signatera® Test Selected for NRG Oncology s Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer

Natera s Signatera® Test Selected for NRG Oncology s Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosMike brophyKate stabrawaArvind dasariAlexey aleshinNatera incNational clinical trials networkClinical laboratory improvement amendmentsNational cancer instituteDrug administrationMd anderson cancer centerResidual diseaseBreakthrough device designations

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosMike brophyKate stabrawaAlexey aleshinNatera incClinical laboratory improvement amendmentsDrug administrationAmerican cancer societyBreakthrough device designationsAmerican cancerஒன்றுபட்டது மாநிலங்களில்சான் கார்லோஸ்மைக் கோப்பைமருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள்அமெரிக்கன் புற்றுநோய் சமூகம்

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Kashiwa shiUnited statesSan carlosMaen abdelrahimHiromichi shirasuMike brophyTakayuki yoshinoKate stabrawaAlexey aleshinNatera incNational cancer center hospitalClinical laboratory improvement amendmentsDrug administrationMedical oncology world congressGastrointestinal cancerPrincipal investigator

Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit

Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosAlexey aleshinThomas powlesNatera incClinical laboratory improvement amendmentsDrug administrationBarts cancer instituteBreakthrough device designationsஒன்றுபட்டது மாநிலங்களில்சான் கார்லோஸ்மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள்மரப்பட்டைகள் புற்றுநோய் நிறுவனம்

Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced initial results from the CIRCULATE-Japan.

Kashiwa shiUnited statesSan carlosMike brophyTakayuki yoshinoKate stabrawaAlexey aleshinNatera incNational cancer center hospitalClinical laboratory improvement amendmentsAmerican society of clinical oncologyNational cancer centerDrug administrationClinical oncologyAnnual meetingPrincipal investigator